Europe Apheresis Market

Europe Apheresis Market Size (2022 to 2027)

The size of the Apheresis Market worth in Europe was valued at USD 0.50 billion in 2022 and estimated to be growing at a CAGR of 8.74% to reach USD 0.76 billion by 2027.

Y-O-Y growth in the incidence of blood disorders such as bleeding disorders and a decrease in platelet count are expected to hike the European Apheresis Market's growth. The growing prevalence of chronic diseases such as cancer and autoimmune diseases, an increasing number of organ donors when needed, further adds fuel to the market's growth rate. Perforation in the occurrence rate of chronic diseases, increasing necessity for source plasma, mounting activities considering the blood safety and growing number of complicated surgical processes, and acceptance of reimbursement policies are projected to lavish the market's need from 2020 to 2025.

Shortage of capable donors, the high costs associated with the apheresis devices, expensiveness involved with the maintenance and installation of these devices are expected to hinder the market growth to a small extent.

This research report on the European Apheresis Market has been segmented and sub-segmented into the following categories:

By Product:

• Devices
• Disposables

By Procedure:

• Donor
• Therapeutic
• Photopheresis

By Application:

• Renal Diseases
• Neurology
• Cancer
• Hematology
• Autoimmune Diseases
• Cardiovascular Diseases

By Technology:

• Centrifuge
• Membrane Separation

By End User:

• Private Blood Collection Centres
• Public Blood Collection Centres
• Hospitals

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regional Analysis:

In Europe, Germany leads the Apheresis market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness about Apheresis, financial strength to procure expensive tools, and favorable reimbursement policies. The European market has a share of 26% Global market. It has a CAGR of 8.74% owing to the presence of less stringent apheresis devices approval regulations and availability of massive untapped opportunities in emerging European countries.

The German apheresis market is anticipated to rule the European market during the forecast period owing to increasing consciousness regarding apheresis and economic strength to obtain high-priced devices. The escalating number of blood donations uses the apheresis devices, and augmenting the number of apheresis therapy procedures is predicted to drive Germany's market. The growing requirement for apheresis that can affect the lesser pathogens in platelets and components to reduce the threat of transfer-transmitted infections is further estimated to favor Germany's market.

France's apheresis market is expected to be another lucrative region in the European market and is anticipated to grow with a CAGR of 12.5% from 2020 to 2025. The rise in healthcare expenses, a huge patient population with a large transmission requirement, is majorly supporting the French market.

The UK market is the third leading country in the European market and is expected to grow at a brisk pace during the forecast period due to technological advancements.

Key players operating in the Europe Apheresis Market profiled in this report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.